Striverdi

Striverdi is a brand name for olodaterol, a long-acting beta-2 agonist (LABA) inhaled bronchodilator used for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It is delivered as an inhalation solution via the Respimat SoftMist inhaler and is typically administered once daily.

Olodaterol acts as a selective agonist at beta-2 adrenergic receptors on airway smooth muscle, causing sustained bronchodilation and improved airflow. It is intended for regular maintenance therapy and is not a rescue medication for acute symptoms. In some treatment plans it may be used with other COPD therapies, including inhaled corticosteroids or long-acting muscarinic antagonists, or in fixed-dose combinations such as olodaterol with tiotropium (Stiolto Respimat) in certain markets.

The medication is administered by inhalation once daily using the Respimat inhaler at the prescribed dose. Proper priming and inhaler technique are important for delivering the dose.

Common adverse reactions include upper respiratory tract irritation, cough, and nasopharyngitis; other possible effects include tachycardia and tremor. Like other LABAs, Striverdi must be used with caution in patients with cardiovascular disease and is not approved for asthma management in adults or children. It should be used as part of a COPD management plan with regular medical supervision.

Striverdi was approved for COPD maintenance by major regulatory authorities and has been marketed globally since the early 2010s. Availability and dosing may vary by country.